Flibanserin Efficacy and Safety in Premenopausal Women with HSDD

Clinical Efficacy

• The American College of Obstetricians and Gynecologists acknowledges that flibanserin 100 mg once daily at bedtime in premenopausal women with HSDD results in approximately 1 additional satisfying sexual event every 2 months compared to placebo 1, 2
• Flibanserin demonstrates statistically significant improvements in sexual desire measured by the Female Sexual Function Index (FSFI) desire domain score, although the exact mechanism remains unclear 2

Important Clinical Considerations

• The National Comprehensive Cancer Network notes that flibanserin has NOT been evaluated in women with a history of cancer or those on endocrine therapy, and the risk/benefit ratio in these populations remains uncertain 3, 4
• The Journal of Clinical Oncology guidelines discuss flibanserin in the context of cancer survivorship care, highlighting the need for further research in this area 2, 3